Johnathan C. Maher

1.1k total citations
18 papers, 892 citations indexed

About

Johnathan C. Maher is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Johnathan C. Maher has authored 18 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 7 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Johnathan C. Maher's work include Cancer, Hypoxia, and Metabolism (10 papers), Prostate Cancer Treatment and Research (4 papers) and Cancer Research and Treatments (3 papers). Johnathan C. Maher is often cited by papers focused on Cancer, Hypoxia, and Metabolism (10 papers), Prostate Cancer Treatment and Research (4 papers) and Cancer Research and Treatments (3 papers). Johnathan C. Maher collaborates with scholars based in United States, Australia and United Kingdom. Johnathan C. Maher's co-authors include Théodore J. Lampidis, Metin Kurtoğlu, Awtar Krishan, Niramol Savaraj, Medhi Wangpaichitr, Ningguo Gao, Andrew N. Lane, Jie Shang, Mark A. Lehrman and Waldemar Priebe and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Johnathan C. Maher

18 papers receiving 882 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johnathan C. Maher United States 10 552 445 190 120 101 18 892
Yunzhao R. Ren United States 10 528 1.0× 340 0.8× 153 0.8× 81 0.7× 71 0.7× 16 942
Katarzyna Marta Lisowska Poland 16 736 1.3× 338 0.8× 295 1.6× 147 1.2× 60 0.6× 36 1.3k
Kate E.R. Hollinshead United States 8 592 1.1× 556 1.2× 206 1.1× 135 1.1× 69 0.7× 11 1.0k
Alisha M. Mendonsa United States 7 478 0.9× 227 0.5× 268 1.4× 99 0.8× 108 1.1× 8 865
Sravanth K. Hindupur Switzerland 11 930 1.7× 489 1.1× 200 1.1× 111 0.9× 165 1.6× 12 1.3k
Marta Martínez Spain 16 717 1.3× 299 0.7× 262 1.4× 177 1.5× 128 1.3× 28 1.2k
Xiaowei Liu China 12 774 1.4× 649 1.5× 114 0.6× 146 1.2× 85 0.8× 27 1.1k
Mitsuyo Ohmura Japan 13 810 1.5× 365 0.8× 295 1.6× 78 0.7× 40 0.4× 17 1.2k
Alessandro Arcucci Italy 16 465 0.8× 257 0.6× 378 2.0× 181 1.5× 77 0.8× 35 948

Countries citing papers authored by Johnathan C. Maher

Since Specialization
Citations

This map shows the geographic impact of Johnathan C. Maher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johnathan C. Maher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johnathan C. Maher more than expected).

Fields of papers citing papers by Johnathan C. Maher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johnathan C. Maher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johnathan C. Maher. The network helps show where Johnathan C. Maher may publish in the future.

Co-authorship network of co-authors of Johnathan C. Maher

This figure shows the co-authorship network connecting the top 25 collaborators of Johnathan C. Maher. A scholar is included among the top collaborators of Johnathan C. Maher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johnathan C. Maher. Johnathan C. Maher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wierda, William G., Andrew W. Roberts, Paolo Ghia, et al.. (2018). Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). 3134–3134. 5 indexed citations
2.
Wierda, William G., John F. Seymour, Andrew W. Roberts, et al.. (2017). Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 130. 4329–4329. 2 indexed citations
3.
Antonarakis, Emmanuel S., Adam S. Kibel, Evan Y. Yu, et al.. (2016). Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clinical Cancer Research. 23(10). 2451–2459. 60 indexed citations
4.
5.
6.
Bajorin, Dean F., Leonard G. Gomella, Padmanee Sharma, et al.. (2014). Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.. Journal of Clinical Oncology. 32(15_suppl). 4541–4541. 5 indexed citations
7.
Flanigan, Robert C., Anthony Polcari, Thomas H. Price, et al.. (2012). An Analysis of Leukapheresis and Central Venous Catheter Use in the Randomized, Placebo Controlled, Phase 3 IMPACT Trial of Sipuleucel-T for Metastatic Castrate Resistant Prostate Cancer. The Journal of Urology. 189(2). 521–526. 13 indexed citations
8.
9.
Wangpaichitr, Medhi, Niramol Savaraj, Johnathan C. Maher, Metin Kurtoğlu, & Théodore J. Lampidis. (2008). Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy- d -glucose under hypoxia in lung cancer cell lines. Molecular Cancer Therapeutics. 7(6). 1506–1513. 30 indexed citations
10.
Wangpaichitr, Medhi, Johnathan C. Maher, Metin Kurtoğlu, Niramol Savaraj, & Théodore J. Lampidis. (2007). Inhibition of mTOR activity potentiates 2-DG-induced cell death in hypoxic cells via down-regulation of HIF-1α. Cancer Research. 67. 4463–4463. 1 indexed citations
11.
Kurtoğlu, Metin, Ningguo Gao, Jie Shang, et al.. (2007). Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Molecular Cancer Therapeutics. 6(11). 3049–3058. 202 indexed citations
12.
Kurtoğlu, Metin, Johnathan C. Maher, & Théodore J. Lampidis. (2007). Differential Toxic Mechanisms of 2-Deoxy-D-Glucose versus 2-Fluorodeoxy-D -Glucose in Hypoxic and Normoxic Tumor Cells. Antioxidants and Redox Signaling. 9(9). 1383–1390. 131 indexed citations
13.
Maher, Johnathan C., Medhi Wangpaichitr, Niramol Savaraj, Metin Kurtoğlu, & Théodore J. Lampidis. (2007). Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose. Molecular Cancer Therapeutics. 6(2). 732–741. 92 indexed citations
14.
Lampidis, Théodore J., Metin Kurtoğlu, Johnathan C. Maher, et al.. (2006). Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing “hypoxic tumor cells”. Cancer Chemotherapy and Pharmacology. 58(6). 725–734. 68 indexed citations
15.
Maher, Johnathan C.. (2006). Treatment of tumor cells with the glycolytic inhibitor, 2-deoxy-D-glucose: Effects and mechanisms of resistance. 1 indexed citations
16.
Kurtoğlu, Metin, Johnathan C. Maher, Awtar Krishan, Waldemar Priebe, & Théodore J. Lampidis. (2005). 2-Deoxy-D-glucose kills select tumor cell types under normoxia: reversal by mannose indicates interference with glycosylation. Cancer Research. 65. 557–557. 1 indexed citations
17.
Maher, Johnathan C., Niramol Savaraj, Waldemar Priebe, Huaping Liu, & Théodore J. Lampidis. (2005). Differential Sensitivity to 2-Deoxy-D-glucose Between Two Pancreatic Cell Lines Correlates With GLUT-1 Expression. Pancreas. 30(2). e34–e39. 41 indexed citations
18.
Maher, Johnathan C., Awtar Krishan, & Théodore J. Lampidis. (2004). Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemotherapy and Pharmacology. 53(2). 116–122. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yunzhao R. Ren Breakdown of academic impact, for papers by Katarzyna Marta Lisowska Breakdown of academic impact, for papers by Kate E.R. Hollinshead Breakdown of academic impact, for papers by Alisha M. Mendonsa Breakdown of academic impact, for papers by Sravanth K. Hindupur Breakdown of academic impact, for papers by Marta Martínez Breakdown of academic impact, for papers by Xiaowei Liu Breakdown of academic impact, for papers by Mitsuyo Ohmura Breakdown of academic impact, for papers by Alessandro Arcucci
Rankless by CCL
2026